Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming events.

BIO-Europe Spring | March 20–22, 2023 | Basel, Switzerland
LSX World Congress | May 3-4, 2023 | London, UK
Redeye Investor Forum | May 11, 2023 | Malmö, Sweden
BioStock Life Science Summit Spring | May 30-31, 2023 | Digital
BIO International Convention | June 5-8, 2023 | Boston, MA, USA
 
“Our phase 1 clinical study on the lead candidate SOL-116 is ongoing and industry meetings provide opportunities to maintain our contacts and present the progress”, says CEO Einar Pontén.

Contacts
Einar Pontén, CEO
E-post: einar.ponten@lipum.se
Mobile: +46 70 578 34 95
Web: www.lipum.se

About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attachments
Lipum to participate in following upcoming events

Lipum to participate in following upcoming events